GlobalData has released its new PharmaPoint Drug Evaluation report, Herceptin (HER2-Positive Breast Cancer) Forecast and Market Analysis to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.
Roche/Genentechs Herceptin (trastuzumab), first approved in the US in 1998, and in the EU in 2000, is the gold-standard treatment for HER2-positive breast cancer, and is prescribed both for patients with early-stage and metastatic disease. Herceptin is an intravenously-administered mAb that targets the HER2 receptor, blocking the downstream signaling pathways that support tumor cell survival (Genentech, 2013).
Reasons to buy